Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
GILD [NASD]
Gilead Sciences Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E34.40 EPS (ttm)1.51 Insider Own0.60% Shs Outstand1.52B Perf Week-0.95%
Market Cap79.02B Forward P/E17.64 EPS next Y2.94 Insider Trans1.64% Shs Float1.51B Perf Month-7.74%
Income2.87B PEG1.31 EPS next Q0.49 Inst Own98.80% Short Float3.57% Perf Quarter17.03%
Sales9.95B P/S7.94 EPS this Y-7.30% Inst Trans1.27% Short Ratio4.44 Perf Half Y39.92%
Book/sh6.67 P/B7.79 EPS next Y49.14% ROA13.50% Target Price65.83 Perf Year107.35%
Cash/sh1.28 P/C40.67 EPS next 5Y26.19% ROE31.90% 52W Range24.80 - 58.06 Perf YTD41.45%
Dividend- P/FCF26.33 EPS past 5Y14.90% ROI16.90% 52W High-10.76% Beta0.51
Dividend %- Quick Ratio1.10 Sales past 5Y18.10% Gross Margin74.60% 52W Low108.91% ATR1.77
Employees5000 Current Ratio1.60 Sales Q/Q10.90% Oper. Margin42.30% RSI (14)44.16 Volatility3.10% 3.37%
OptionableYes Debt/Eq0.79 EPS Q/Q53.60% Profit Margin28.90% Rel Volume0.34 Prev Close51.94
ShortableYes LT Debt/Eq0.69 EarningsJul 22 Payout0.00% Avg Volume12.18M Price51.81
Recom1.80 SMA20-3.05% SMA50-2.20% SMA20024.19% Volume344,525 Change-0.25%
13-Jun-13Upgrade Argus Hold → Buy
17-May-13Reiterated UBS Buy $63 → $67
03-May-13Reiterated Oppenheimer Outperform $59 → $61
03-May-13Reiterated Needham Buy $45 → $62
29-Apr-13Reiterated RBC Capital Mkts Outperform $55 → $62
22-Apr-13Reiterated Maxim Group Buy $48 → $97
17-Apr-13Reiterated Oppenheimer Outperform $50 → $59
16-Apr-13Reiterated Deutsche Bank Buy $48 → $69
15-Apr-13Reiterated Barclays Overweight $42 → $65
09-Apr-13Reiterated RBC Capital Mkts Outperform $50 → $55
25-Mar-13Reiterated Maxim Group Buy $43 → $48
14-Mar-13Reiterated Oppenheimer Outperform $45 → $50
28-Feb-13Reiterated RBC Capital Mkts Outperform $44 → $50
05-Feb-13Reiterated UBS Buy $47 → $48
05-Feb-13Reiterated Stifel Nicolaus Buy $45 → $49
05-Feb-13Reiterated Needham Buy $37.50 → $45
30-Jan-13Reiterated UBS Buy $43.50 → $47
22-Jan-13Reiterated Barclays Overweight $76 → $84
04-Jan-13Resumed Robert W. Baird Outperform $86
18-Dec-12Reiterated UBS Buy $80 → $87
19-Jun-13 09:13AM  Amgen In Focus at Seeking Alpha
18-Jun-13 06:01PM  Final Glance: Biotechnology companies AP
01:17PM  Midday Glance: Biotechnology companies AP
12:34PM  The Best Healthcare Bet at Motley Fool
11:34AM  An Interview With Elemer Piros: A Strong Year For Biotechs, Looking From The Halfway Point at Seeking Alpha
10:21AM  Early Glance: Biotechnology companies AP
17-Jun-13 07:08PM  Todays 3 Worst Stocks at Motley Fool
06:04PM  Final Glance: Biotechnology companies AP
05:01PM  Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard at TheStreet
04:30PM  Gilead Sciences to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18 Business Wire
01:30PM  Midday Glance: Biotechnology companies AP
10:47AM  Huge Upside on Pipeline Strength at Motley Fool
10:29AM  Early Glance: Biotechnology companies AP
08:17AM  Gilead's Potential Megablockbuster Raises the Bar at Motley Fool
04:54AM  InPlay: Gilead Sciences reports interim Phase 2 data for Idelalisib showing response in refractory indolent non-hodgkin's lymphoma Briefing.com
04:00AM  Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkins Lymphoma Business Wire
15-Jun-13 08:01AM  3 Key Advances in HIV Prevention at Motley Fool
14-Jun-13 06:03PM  Final Glance: Biotechnology companies AP
01:28PM  Midday Glance: Biotechnology companies AP
12:47PM  Stanley Druckenmiller's new stock picks at MarketWatch
10:37AM  Early Glance: Biotechnology companies AP
07:41AM  Consider Biotech Gilead Sciences Because Of Atripla, Sofosbuvir And Great R&D at Seeking Alpha
07:00AM  Biotech Stock Mailbag: Exact Sciences, Questcor, Biotech M&A, Celsion at TheStreet
13-Jun-13 07:10PM  [video] SCOTUS: Human Genes Can't Be Patented at CNBC
06:19PM  4 Healthcare Stock Stories Getting Notice On Thursday at Wall St. Cheat Sheet
06:03PM  Final Glance: Biotechnology companies AP
04:30PM  AbbVie Says It Can Be First With New Hepatitis C Drugs at Bloomberg
03:42PM  [video] Myriad Hits Historic High at CNBC
02:36PM  [video] Myriad Gets Partial Win In Ruling at CNBC
02:20PM  Thursday's Top Upgrades (and Downgrades) at Motley Fool
01:17PM  Midday Glance: Biotechnology companies AP
11:44AM  China Biologic: A Star Small-Cap Pick From China at Seeking Alpha
10:22AM  Early Glance: Biotechnology companies AP
09:39AM  Inside HCV: An Interview with Janssen at Motley Fool
09:20AM  Stock Upgrades: Bulls Run on Adidas AG at Minyanville
07:13AM  HIV drug can also protect injection drug users AP
01:23AM  Gilead Sciences upgraded by Argus Briefing.com
12-Jun-13 06:11PM  Final Glance: Biotechnology companies AP
02:43PM  Gileads Viread Reduces HIV Risk for Drug Users in Study at Bloomberg
01:38PM  Biogen Stock Dips On Concerns Of MS Drug Protection at Investor's Business Daily
01:17PM  Midday Glance: Biotechnology companies AP
12:04PM  AIDS drugs halve HIV risk for intravenous drug users in study at Reuters
11:38AM  Biogen Tumbles On Citi Downgrade at Barrons.com
11:00AM  Warning: This Might Be The Most Overvalued Sector In The Market StreetAuthority Network
11:00AM  Warning: This Might Be The Most Overvalued Sector In The Market
10:32AM  Early Glance: Biotechnology companies AP
10:31AM  2 Services Sector Companies And 1 Biotech With Recent Intensive Insider Selling at Seeking Alpha
11-Jun-13 07:36PM  Game-Changing Hep C Pill Closer to Approval at Motley Fool
06:07PM  Final Glance: Biotechnology companies AP
05:51PM  Apple: Why Fidelity's Jason Weiner Still Likes It at Investor's Business Daily
01:21PM  Midday Glance: Biotechnology companies AP
10:31AM  Early Glance: Biotechnology companies AP
09:00AM  Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Sales at TheStreet
08:40AM  3 Impressive Biotech ETFs Crushing the Market Zacks
10-Jun-13 06:08PM  Big Cap 20 Outperforming S&P 500, IBD 50 Too at Investor's Business Daily
06:04PM  Final Glance: Biotechnology companies AP
04:34PM  Former Bristol-Myers executive admits to insider trading Reuters
04:30PM  Gilead Sciences to Present at the Goldman Sachs 34th Annual Healthcare Conference on Tuesday, June 11 Business Wire
03:08PM  [$$] Gilead on the Fast Track at Barrons.com
01:19PM  Midday Glance: Biotechnology companies AP
12:51PM  Infinity Pharma's Safety Concerns: For Patient Investors, A Buying Opportunity at Seeking Alpha
09:55AM  [video] Cramer's Six in 60: MU, ETR, HPQ at CNBC
09:54AM  Infinity Pharmaceuticals And IPI-145: ASCO 2013 Highlights at Seeking Alpha
09:10AM  Morning Round-Up: Stocks Gain As Japan Rises, McDonald's May Sales Beat at Barrons.com
08:40AM  Priority Review for Gilead Drug Zacks
07:00AM  Winners And Losers in CLL at ASCO '13 at TheStreet
08-Jun-13 03:10PM  Gilead Anti-Hep-C Treatment on the FDA Fast Track at Motley Fool
09:15AM  3 Horrendous Health-Care Stocks This Week at Motley Fool
07-Jun-13 06:08PM  FDA grants priority review status to Gilead's hepatitis C drug at Reuters
06:02PM  Final Glance: Biotechnology companies AP
05:48PM  Gileads Hepatitis C Drug to Get Priority Review by FDA at Bloomberg
05:19PM  InPlay: Gilead Sciences announces U.S. FDA Priority Review designation for sofosbuvir for the treatment of hepatitis C Briefing.com
05:19PM  Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C Business Wire
01:22PM  Midday Glance: Biotechnology companies AP
12:33PM  Cramer: The Market Welcomes the Jobs Number at TheStreet
11:58AM  Gilead Sciences: Buy Stance For Investors at Seeking Alpha
10:25AM  Early Glance: Biotechnology companies AP
10:00AM  Gilead Sciences Inc Stock Buy Recommendation Reiterated (GILD) at TheStreet
06-Jun-13 06:07PM  Final Glance: Biotechnology companies AP
03:56PM  Gilead's Entry Into Cancer Therapy at Motley Fool
02:39PM  [video] S&P Best & Worst at CNBC
01:20PM  Midday Glance: Biotechnology companies AP
10:29AM  Early Glance: Biotechnology companies AP
09:31AM  Critical Alerts For Nike, Gilead Sciences, HollyFrontier, Brown-Forman, and IMAX Released By InvestorsObserver PR Newswire
05-Jun-13 06:04PM  Final Glance: Biotechnology companies AP
02:00PM  The Upside Of A Stock With The Security Of A Bond? StreetAuthority Network
02:00PM  The Upside Of A Stock With The Security Of A Bond?
01:37PM  3 Stocks to Get on Your Watchlist at Motley Fool
01:17PM  Midday Glance: Biotechnology companies AP
10:31AM  Early Glance: Biotechnology companies AP
04-Jun-13 06:02PM  Final Glance: Biotechnology companies AP
01:16PM  Midday Glance: Biotechnology companies AP
01:04PM  CELG, AMGN, GILD, JNJ And PFE, Pushing Drugs Industry Downward at TheStreet
10:36AM  Early Glance: Biotechnology companies AP
03-Jun-13 06:45PM  EU Approval of Blockbuster Drug Could Mean Big Returns From This Pharma Giant StreetAuthority Network
06:45PM  EU Approval of Blockbuster Drug Could Mean Big Returns From This Pharma Giant
06:15PM  Final Glance: Biotechnology companies AP
06:02PM  Cramer: Out with the New, In with the Old at CNBC
05:30PM  [video] Big Pharma On the Move at CNBC
04:21PM  Stock Market Trims Losses As Indexes Close Mixed at Investor's Business Daily
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorJun 07Option Exercise10.99110,0001,209,175149,542Jun 11 02:41 PM
Cogan John FrancisDirectorJun 07Sale52.15110,0005,736,88539,542Jun 11 02:41 PM
Alton Gregg HEVP, Corp & Med AffairsJun 03Option Exercise16.4026,000426,27089,938Jun 05 05:26 PM
MARTIN JOHN CChairman and CEOJun 03Option Exercise7.63282,2422,154,2124,339,363Jun 05 06:36 PM
Alton Gregg HEVP, Corp & Med AffairsJun 03Sale52.7730,0001,583,12159,938Jun 05 05:26 PM
MARTIN JOHN CChairman and CEOJun 03Sale52.84282,24214,912,8714,057,121Jun 05 06:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise7.63282,2422,154,2124,339,363May 03 06:15 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise16.4026,000426,27093,938May 03 05:12 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale50.2030,0001,506,12363,938May 03 05:12 PM
MARTIN JOHN CChairman and CEOMay 01Sale50.17282,24214,160,9564,057,121May 03 06:15 PM
Washington Robin LSVP, CFOApr 11Sale50.2096848,59427,130Apr 15 02:42 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise16.4026,000426,27097,938Apr 03 06:16 PM
Washington Robin LSVP, CFOApr 01Option Exercise26.5713,000345,41538,098Apr 03 06:17 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise7.63282,2422,154,2124,339,363Apr 03 04:26 PM
Washington Robin LSVP, CFOApr 01Sale48.3313,000628,32928,098Apr 03 06:17 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale48.3730,0001,451,08067,938Apr 03 06:16 PM
MARTIN JOHN CChairman and CEOApr 01Sale48.30282,24213,633,5344,057,121Apr 03 04:26 PM
Washington Robin LSVP, CFOMar 27Option Exercise27.0745,0001,218,15073,098Mar 29 12:54 PM
Washington Robin LSVP, CFOMar 27Sale47.0745,0002,118,15028,098Mar 29 12:54 PM
Washington Robin LSVP, CFOMar 14Sale45.854,304197,32128,098Mar 18 07:43 PM
Washington Robin LSVP, CFOMar 05Option Exercise24.3045,0001,093,27568,794Mar 06 06:23 PM
Washington Robin LSVP, CFOMar 05Sale44.4145,0001,998,45023,794Mar 06 06:23 PM
Washington Robin LSVP, CFOMar 04Option Exercise23.689,800232,02433,594Mar 06 06:23 PM
Washington Robin LSVP, CFOMar 04Sale43.689,800428,04823,794Mar 06 06:23 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise7.63282,2422,154,2124,288,674Mar 05 05:13 PM
Alton Gregg HEVP, Corp & Med AffairsMar 01Option Exercise16.4026,000426,27088,548Mar 05 04:07 PM
Alton Gregg HEVP, Corp & Med AffairsMar 01Sale43.0830,0001,292,44258,548Mar 05 04:07 PM
MARTIN JOHN CChairman and CEOMar 01Sale43.14282,24212,176,0634,006,432Mar 05 05:13 PM
WOLD OLSEN PERDirectorFeb 28Buy43.0510,000430,49369,458Mar 04 03:57 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise7.63282,2422,154,2124,287,706Feb 05 04:47 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 01Option Exercise15.5926,000405,29191,580Feb 05 04:49 PM
MARTIN JOHN CChairman and CEOFeb 01Sale40.43282,24211,410,4774,005,464Feb 05 04:47 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 01Sale40.4230,0001,212,52061,580Feb 05 04:49 PM
Washington Robin LSVP, CFOJan 28Option Exercise19.0911,550220,43234,376Jan 30 01:29 PM
Washington Robin LSVP, CFOJan 28Sale39.4811,550456,02422,826Jan 30 01:29 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise30.18113,0003,410,705147,790Jan 04 03:49 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise15.27141,1212,154,2122,143,853Jan 04 03:49 PM
MARTIN JOHN CChairman and CEOJan 02Sale74.46141,12110,508,4722,002,732Jan 04 03:49 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale74.63115,0008,582,71132,790Jan 04 03:49 PM
MARTIN JOHN CChairman and CEODec 10Option Exercise15.6312,794199,9542,002,732Dec 12 03:09 PM
MARTIN JOHN CChairman and CEODec 03Option Exercise8.94145,5001,301,1342,135,438Dec 05 06:30 PM
Alton Gregg HEVP, Corp & Med AffairsDec 03Option Exercise29.0121,000609,10556,790Dec 05 06:30 PM
MARTIN JOHN CChairman and CEODec 03Sale75.01145,50010,914,5931,989,938Dec 05 06:30 PM
Alton Gregg HEVP, Corp & Med AffairsDec 03Sale75.1022,0001,652,24134,790Dec 05 06:30 PM
MOORE NICHOLAS GDirectorNov 30Option Exercise28.6865,0001,863,87572,309Dec 04 04:51 PM
MOORE NICHOLAS GDirectorNov 30Sale74.9665,0004,872,5507,309Dec 04 04:51 PM
DENNY JAMES MDirectorNov 28Option Exercise23.3864,0001,496,092301,158Nov 30 01:53 PM
DENNY JAMES MDirectorNov 28Sale73.9120,0001,478,224281,158Nov 30 01:53 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Option Exercise53.2427,9751,489,48033,913Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 12Sale73.1127,9752,045,31111,413Nov 14 06:48 PM
Washington Robin LSVP, CFONov 07Option Exercise54.142,500135,35015,512Nov 09 05:16 PM
Washington Robin LSVP, CFONov 07Sale66.304,099271,76511,413Nov 09 05:16 PM
Washington Robin LSVP, CFONov 05Option Exercise0.003,000014,413Nov 07 06:18 PM
MILLIGAN JOHN FPresident and COONov 02Option Exercise17.5070,0001,224,825340,187Nov 06 03:31 PM
MILLIGAN JOHN FPresident and COONov 02Sale67.0170,0004,690,672270,187Nov 06 03:31 PM
MARTIN JOHN CChairman and CEONov 01Option Exercise8.94145,4501,300,6872,135,388Nov 05 06:22 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Option Exercise29.0121,000609,10557,790Nov 05 08:25 PM
Metza KristenSVP, Human ResourcesNov 01Option Exercise42.8630,0001,285,82055,305Nov 05 08:26 PM
Whitley Richard JamesDirectorNov 01Sale67.817,226490,0063,632Nov 05 08:26 PM
Metza KristenSVP, Human ResourcesNov 01Sale67.7230,0002,031,66625,305Nov 05 08:26 PM
Alton Gregg HEVP, Corp & Med AffairsNov 01Sale67.8022,0001,491,59835,790Nov 05 08:25 PM
MARTIN JOHN CChairman and CEONov 01Sale67.70145,4509,847,5901,989,938Nov 05 06:22 PM
Washington Robin LSVP, CFOOct 31Option Exercise48.392,925141,55413,213Nov 02 02:38 PM
Washington Robin LSVP, CFOOct 31Sale67.632,925197,81611,413Nov 02 02:38 PM
MILLIGAN JOHN FPresident and COOOct 29Option Exercise8.9411,18099,977270,187Oct 31 12:46 PM
DAVIGNON ETIENNEDirectorOct 26Sale67.2420,0001,344,850582,934Oct 30 07:35 PM
Washington Robin LSVP, CFOOct 24Option Exercise47.2062529,50012,038Oct 26 05:44 PM
Washington Robin LSVP, CFOOct 24Sale68.4562542,78111,413Oct 26 05:44 PM
Washington Robin LSVP, CFOOct 22Option Exercise40.387,650308,93217,188Oct 24 04:10 PM
Washington Robin LSVP, CFOOct 22Sale66.167,650506,13411,413Oct 24 04:10 PM
MILLIGAN JOHN FPresident and COOOct 03Option Exercise17.5070,0001,224,825329,007Oct 05 01:00 PM
MILLIGAN JOHN FPresident and COOOct 03Sale69.8570,0004,889,241259,007Oct 05 01:00 PM
Washington Robin LSVP, CFOOct 02Option Exercise47.3314,750698,06020,163Oct 04 03:29 PM
Washington Robin LSVP, CFOOct 02Sale68.6214,7501,012,19111,413Oct 04 03:29 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise29.0121,000609,10558,790Oct 03 12:46 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.94145,4501,300,6872,135,388Oct 03 12:46 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale67.6622,0001,488,57936,790Oct 03 12:46 PM
MARTIN JOHN CChairman and CEOOct 01Sale67.53145,4509,822,6321,989,938Oct 03 12:46 PM
Washington Robin LSVP, CFOSep 18Option Exercise49.814,500224,14515,913Sep 19 07:34 PM
Washington Robin LSVP, CFOSep 18Sale67.254,500302,62511,413Sep 19 07:34 PM
Washington Robin LSVP, CFOSep 17Option Exercise52.3857,2502,999,01053,913Sep 19 07:34 PM
Washington Robin LSVP, CFOSep 17Sale64.8357,2503,711,34611,413Sep 19 07:34 PM
Metza KristenSVP, Human ResourcesSep 13Option Exercise41.4675,0003,109,65062,805Sep 17 06:21 PM
Metza KristenSVP, Human ResourcesSep 13Sale59.9590,0005,395,50025,305Sep 17 06:21 PM
Washington Robin LSVP, CFOSep 10Option Exercise49.819,000448,29020,413Sep 11 06:32 PM
Washington Robin LSVP, CFOSep 10Sale59.789,000538,02011,413Sep 11 06:32 PM
Alton Gregg HEVP, Corp & Med AffairsSep 04Option Exercise29.0121,000609,10559,790Sep 06 06:40 PM
MARTIN JOHN CChairman and CEOSep 04Option Exercise8.94145,4501,300,6872,135,388Sep 06 08:33 PM
MILLIGAN JOHN FPresident and COOSep 04Option Exercise17.50140,0002,449,650399,007Sep 06 08:33 PM
MILLIGAN JOHN FPresident and COOSep 04Sale57.41140,0008,037,694259,007Sep 06 08:33 PM
MARTIN JOHN CChairman and CEOSep 04Sale57.68145,4508,390,0131,989,938Sep 06 08:33 PM
Alton Gregg HEVP, Corp & Med AffairsSep 04Sale57.5022,0001,265,06237,790Sep 06 06:40 PM
Metza KristenSVP, Human ResourcesSep 01Option Exercise47.2015,000708,00040,305Sep 17 06:21 PM
Washington Robin LSVP, CFOAug 30Sale57.483,466199,23911,413Sep 04 01:01 PM
open in yahoo | open in reuters | open in google